Literature DB >> 8625052

Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis.

S Heegaard1, H M Sommer, H Broholm, O Broendstrup.   

Abstract

BACKGROUND: The biologic behavior of oligodendrogliomas is somewhat unpredictable. A supplementary prognostic factor is, therefore, desirable.
METHODS: Thirty-two pure supratentorial oligodendrogliomas were investigated using proliferating cell nuclear antigen (PCNA) and Ki-67 immunohistochemical analyses. The correlation of PCNA and Ki-67 labeling index (LI) with prognosis were studied, and the correlation of LI with clinical data was evaluated.
RESULTS: The PCNA LI had a range of 0-17% (mean, 5.27%; standard deviation [SD] = 4.65), and the Ki-67 LI had a range of 0-29% (mean, 4.19%; SD = 5.66). In general, the PCNA LI seemed to be higher than the Ki-67 LI. The mean survival time was 4.4 years, and 5- and 10-year survival rates were 38% and 19%, respectively. Ki-67 and PCNA staining indicated that patients with a high LI (> 3% and > 4%, respectively) had a significantly higher mortality, with mean survival time of 23.5 months and 26.2 months, respectively. No significant correlation between LI (or survival) and tumor size, cerebral localization, radiation, resection/biopsy, sex, age, or cytologic atypia was found.
CONCLUSIONS: The use of Ki-67 and PCNA LI higher than 3% and 4%, respectively, appears reliable as prognostic factors when investigating pure supratentorial oligodendrogliomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8625052     DOI: 10.1002/1097-0142(19951115)76:10<1809::aid-cncr2820761020>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.

Authors:  Ali Chahlavi; Andrew Kanner; David Peereboom; Susan M Staugaitis; Paul Elson; Gene Barnett
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

3.  The prognostic role of vessel productive changes and vessel density in oligodendroglioma.

Authors:  D Schiffer; I Bosone; A Dutto; N Di Vito; A Chiò
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

4.  Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.

Authors:  Xian-Zeng Hou; Wei Liu; Hai-Tao Fan; Bin Liu; Bo Pang; Tao Xin; Shang-Chen Xu; Qi Pang
Journal:  Neuro Oncol       Date:  2010-03-03       Impact factor: 12.300

5.  Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas.

Authors:  Roland Schröder; Klaus D Feisel; Ralf-Ingo Ernestus
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

6.  Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.

Authors:  M A Heesters; J Koudstaal; K G Go; W M Molenaar
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 7.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

Review 8.  Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults.

Authors:  Lynn S Ashby; William R Shapiro
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

9.  Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors.

Authors:  Haihui Jiang; Xiaohui Ren; Zhe Zhang; Wei Zeng; Junmei Wang; Song Lin
Journal:  J Neurooncol       Date:  2014-07-10       Impact factor: 4.130

10.  Immunohistochemical markers for prognosis of oligodendroglial neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.